February 24, 2010 | Expression Analysis Completes Illumina CSPro
EA says it is now the only genomic service provider, globally, to be fully certified on all Illumina applications. Illumina CSPro is a collaborative service provider partnership dedicated to ensuring the delivery of the highest-quality data available for genetic analysis applications. Expression Analysis underwent a rigorous two-phase certification process, for all four platforms, that included minimum data generation, data certification, and an on-site audit of the facility and processes. Read release.
Waters announced a collaborative agreement to globally market and supply DAISOGEL bulk packing materials for process chromatography. The combined purification expertise of both organizations will aid pharmaceutical and biopharmaceutical companies as they move from lab-scale purifications into pilot plant and process-scale manufacturing.
To simplify scaling-up purification methods, DAISOGEL columns are packed using Waters patented Optimum Bed Density Technology1. OBD Technology enables analytical column performance and industry best lifetime in larger preparative columns. The companies say scientists will save time by eliminating the need for subsequent method redevelopment as they increase in scale. Reads release.
Beckman Coulter 4Q Revenue Up 22%
Beckman Coulter reported fourth quarter and full year ended December 31, 2009 results. 4Q revenue, including $120.2 million from the recent Olympus Diagnostics (Olympus) acquisition, was $989.6 million, up 22% over prior year quarter, or 17.8% in constant currency. Reported net earnings were $64.2 million. More information.
Agilent Technologies Genomics GM
Agilent announced appointments of Robert Schueren as VP and general manager, Genomics; and John Fjeldsted, Ph.D., as general manager, Liquid Chromatography/Mass Spectrometry. Schueren will be responsible for all genomics operations, including microarrays, QPCR and life science reagents. Most recently, he was global head of companion diagnostics, clinical biomarker, and sample operations at Genentech/Roche.
Fjeldsted will be responsible for managing the LC/MS business and driving market share in high-end LC/MS. He has been with Agilent for more than 25 years and played a key role in the tremendous growth of Agilent’s LC/MS unit. Most recently, he served as R&D manager for LC/MS as Agilent entered the LC/MS business with triple quadrupole and QTOF mass spectrometers.
Ingenuity Announces Weekly Updates
Ingenuity Systems is adding weekly content updates, and metabolomics workflow support in the latest release of IPA software. "The combination of weekly content updates with the new dynamic reports in IPA 8.5 helped numerous translational medicine and systems biology projects at the Erasmus MC to create clear and targeted summaries for several relevant genes associated with the disease we are studying," stated Dr. Andreas Kremer, Research Scientist, Erasmus Medical Center. Other high impact features in IPA 8.5 include streamlined metabolomics workflows, collaborative workspaces, and new pathway and disease content.
Separately the company announced appointment of an exclusive South Korean distributor, SeouLin Bioscience Co., Ltd. as the exclusive distributor of IPA in South Korea. This partnership is the latest expansion for Ingenuity Systems in the Asia Pacific market. Ingenuity products and services are already distributed in Singapore, Taiwan, Japan, and Australia and New Zealand.
MDS Inc. Divests Pharma Services
MDS, a provider of products and services to the global life sciences markets, reports agreements to divest its remaining MDS Pharma Services Early Stage business, which provides Discovery through Phase IIa clinical trial services to biotechnology and pharmaceutical companies, for $45 million and certain minority equity interests.
Upon the close of the sale, MDS will have completed its repositioning strategy and will focus on building its MDS Nordion business, which has strong positions in medical imaging and radiotherapeutics, and sterilization technologies.
"The agreements to divest the MDS Pharma Services business are the last major milestone in the repositioning of the Company," said Steve West, Chief Executive Officer of MDS Inc. "While the sale agreements have been struck in a difficult environment, we believe we are doing what's necessary to allow us to focus on building MDS Nordion to create shareholder value over the long term."
Under the terms of the agreements, MDS will divest its Discovery and Pre-Clinical operations in Bothell, Washington; Lyon, France; and Taipei, Taiwan, to Ricerca Biosciences LLC, a leading provider of early-stage contract research organization (CRO) services.
"We are evolving to meet the needs of our clients. This expansion, combined with our existing infrastructure, puts us on the forefront of providing comprehensive discovery and preclinical services from Intellectual Property to Investigational New Drugs to the biopharmaceutical industry," said Ian Lennox, Chairman and Chief Executive Officer, Ricerca Biosciences.
BTC Releases AB Report
BioProcess Technology Consultants announced publication of The Development of Therapeutic Monoclonal Antibody Products, a 334-page comprehensive review and analysis of the Chemistry, Manufacturing, and Control (CMC) activities and regulatory requirements for the development of monoclonal antibody products, from initial discovery, through First-In-Human clinical trials.
The report was produced with input and review by GE Healthcare, also includes information on late-stage development and commercialization of these important biologic products and presents strategies for accelerating their development while minimizing risks and costs. More information.